Application of aptamers for targeted therapeutics

Archivum Immunologiae et Therapiae Experimentalis

Volumn 61, Issue 4, 2013, Pages 255-271

  Ray, Partha ^a   Viles, Kristi D ^a   Soule, Erin E ^a   Woodruff, Rebecca Smock ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aptamers; Systematic evolution of ligands by exponential enrichment (SELEX); Targeted therapy

Indexed keywords

9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; ANTINEOPLASTIC AGENT; APTAMER; AS 1411; CELL SURFACE PROTEIN; CETUXIMAB; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; GEMCITABINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; IMMUNOGLOBULIN MU CHAIN; MACROGOL; MICRORNA 221; MUCIN 1; NANOPARTICLE; NUCLEOLIN; PACLITAXEL; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 7; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TENASCIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; COMBINATORIAL CHEMISTRY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG UPTAKE; GENE INACTIVATION; HUMAN; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEIC ACID ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; APTAMERS, NUCLEOTIDE; DRUG CARRIERS; HUMANS; LIGANDS; MEMBRANE PROTEINS; PROTEIN BINDING; SELEX APTAMER TECHNIQUE;

EID: 84879842849     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-013-0227-0     Document Type: Review

References (167)

1. Adler A, Forster N, Homann M et al (2008) Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer. Comb Chem High Throughput Screen 11:16-23
2. Alexis F, Pridgen E, Molnar LK et al (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505-515
3. Aravind A, Jeyamohan P, Nair R et al (2012) AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng 109:2920-2931
4. Bagalkot V, Zhang L, Levy-Nissenbaum E et al (2007) Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 7:3065-3070 (Pubitemid 350132931)
5. Barciszewski J, Medgaard M, Koch T et al (2009) Locked nucleic acid aptamers. Methods Mol Biol 535:165-186
6. Bates PJ, Kahlon JB, Thomas SD et al (1999) Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 274:26369-26377 (Pubitemid 29437088)
7. Bates PJ, Laber DA, Miller DM et al (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86:151-164
8. Bayrac AT, Sefah K, Parekh P et al (2011) In vitro selection of DNA aptamers to glioblastoma multiforme. ACS Chem Neurosci 2:175-181
9. Becker RC, Rusconi C, Sullenger B (2005) Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb Haemost 93:1014-1020 (Pubitemid 40823502)
10. Becker RC, Oney S, Becker KC et al (2007) Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy. Hamostaseologie 27:378-382
11. Berger EA, Doms RW, Fenyo EM et al (1998) A new classification for HIV-1. Nature 391:240 (Pubitemid 28099002)
12. Bombardelli L, Cavallaro U (2010) Immunoglobulin-like cell adhesion molecules: novel signaling players in epithelial ovarian cancer. Int J Biochem Cell Biol 42:590-594
13. Borkowski S, Dinkelborg LM (2006) Aptamers for in vivo imaging. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 343-362
14. Bunka DH, Platonova O, Stockley PG (2010) Development of aptamer therapeutics. Curr Opin Pharmacol 10:557-562
15. Cambier JC, Campbell KS (1992) Membrane immunoglobulin and its accomplices: new lessons from an old receptor. FASEB J 6:3207-3217
16. Cerchia L, Esposito CL, Camorani S et al (2012) Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther 20:2291-2303
17. Chelliserrykattil J, Ellington AD (2004) Evolution of a T7 RNA polymerase variant that transcribes 2′-O-methyl RNA. Nat Biotechnol 22:1155-1160 (Pubitemid 39166855)
18. Chen CH, Dellamaggiore KR, Ouellette CP et al (2008) Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA 105:15908-15913
19. Cho HS, Dong Z, Pauletti GM et al (2010) Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment. ACS Nano 4:5398-5404
20. Chu TC, Marks JW 3rd, Lavery LA et al (2006a) Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res 66:5989-5992
21. Chu TC, Twu KY, Ellington AD et al (2006b) Aptamer mediated siRNA delivery. Nucleic Acids Res 34:e73 (Pubitemid 44540445)
22. Cohen C, Forzan M, Sproat B et al (2008) An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Virology 381:46-54
23. Dalgleish AG, Beverley PC, Clapham PR et al (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763-767 (Pubitemid 15195924)
24. Daniels DA, Chen H, Hicke BJ et al (2003) A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 100:15416-15421 (Pubitemid 38021004)
25. Dassie JP, Liu XY, Thomas GS et al (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839-849
26. Derenzini M, Sirri V, Trere D et al (1995) The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab Invest 73:497-502
27. Dey AK, Griffiths C, Lea SM et al (2005a) Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA 11:873-884 (Pubitemid 40994198)
28. Dey AK, Khati M, Tang M et al (2005b) An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J Virol 79:13806-13810 (Pubitemid 41508193)
29. Dhar S, Gu FX, Langer R et al (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105:17356-17361
30. Dhar S, Kolishetti N, Lippard SJ et al (2011) Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 108:1850-1855
31. Ditzler MA, Bose D, Shkriabai N et al (2011) Broad-spectrum aptamer inhibitors of HIV reverse transcriptase closely mimic natural substrates. Nucleic Acids Res 39:8237-8247
32. Doudna JA, Cech TR, Sullenger BA (1995) Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc Natl Acad Sci USA 92:2355-2359
33. Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20:5623-5637 (Pubitemid 32928102)
34. Eaton BE, Gold L, Zichi DA (1995) Let's get specific: the relationship between specificity and affinity. Chem Biol 2:633-638
35. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-822 (Pubitemid 20272100)
36. Esposito CL, Passaro D, Longobardo I et al (2011) A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS ONE 6:e24071
37. Eulberg D, Jarosch F, Vonhoff S et al (2006) Spiegelmers for therapeutic applications - use of chiral principles in evolutionary selection techniques. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 417-442
38. Fabiilli ML, Haworth KJ, Sebastian IE et al (2010) Delivery of chlorambucil using an acoustically triggered perfluoropentane emulsion. Ultrasound Med Biol 36:1364-1375
39. Farokhzad OC, Cheng J, Teply BA et al (2006a) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103:6315-6320
40. Farokhzad OC, Karp JM, Langer R (2006b) Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 3:311-324 (Pubitemid 43772708)
41. Ferreira CS, Matthews CS, Missailidis S (2006) DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol 27:289-301 (Pubitemid 44646223)
42. Ferreira CS, Cheung MC, Missailidis S et al (2009) Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res 37:866-876
43. Fickert H, Fransson IG, Hahn U (2006) Aptamers to small molecules. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 94-115
44. Fitzwater T, Polisky B (1996) A SELEX primer. Methods Enzymol 267:275-301 (Pubitemid 26159229)
45. Gao J, Gu H, Xu B (2009) Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc Chem Res 42:1097-1107
46. Gao H, Qian J, Cao S et al (2012a) Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 33:5115-5123
47. Gao H, Qian J, Yang Z et al (2012b) Whole-cell SELEX aptamer- functionalised poly(ethyleneglycol)-poly(epsilon-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 33:6264-6272
48. Gendler SJ (2001) MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 6:339-353 (Pubitemid 39600492)
49. Ghosh A, Heston WD (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539
50. Ginisty H, Amalric F, Bouvet P (1998) Nucleolin functions in the first step of ribosomal RNA processing. EMBO J 17:1476-1486 (Pubitemid 28105526)
51. Ginisty H, Sicard H, Roger B et al (1999) Structure and functions of nucleolin. J Cell Sci 112(Pt 6):761-772 (Pubitemid 29179310)
52. Gold L, Polisky B, Uhlenbeck O et al (1995) Diversity of oligonucleotide functions. Annu Rev Biochem 64:763-797
53. Gref R, Minamitake Y, Peracchia MT et al (1994) Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603 (Pubitemid 24128361)
54. Guo J, Gao X, Su L et al (2011) Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32:8010-8020
55. Hicke BJ, Marion C, Chang YF et al (2001) Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 276:48644-48654
56. Hicke BJ, Stephens AW, Gould T et al (2006) Tumor targeting by an aptamer. J Nucl Med 47:668-678 (Pubitemid 46768469)
57. Hovanessian AG, Soundaramourty C, El Khoury D et al (2010) Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS ONE 5:e15787
58. Hu Y, Duan J, Zhan Q et al (2012) Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS ONE 7:e31970
59. Huang Y, Shi H, Zhou H et al (2006) The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 107:3564-3571
60. Huang YF, Shangguan D, Liu H et al (2009) Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem 10:862-868
61. Huang J, Xu JS, Xu RX (2010) Heat-sensitive microbubbles for intraoperative assessment of cancer ablation margins. Biomaterials 31:1278-1286
62. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354 (Pubitemid 40637826)
63. Ireson CR, Kelland LR (2006) Discovery and development of anticancer aptamers. Mol Cancer Ther 5:2957-2962 (Pubitemid 46092036)
64. Jing N, Rando RF, Pommier Y et al (1997) Ion selective folding of loop domains in a potent anti-HIV oligonucleotide. Biochemistry 36:12498-12505 (Pubitemid 27446673)
65. Joseph LF, Ezhevsky S, Scott DW (1995) Lymphoma models for B-cell activation and tolerance: anti-immunoglobulin M treatment induces growth arrest by preventing the formation of an active kinase complex which phosphorylates retinoblastoma gene product in G1. Cell Growth Differ 6:51-57
66. Kang H, O'Donoghue MB, Liu H et al (2010) A liposome-based nanostructure for aptamer directed delivery. Chem Commun 46:249-251
67. Kang H, Liu H, Zhang X et al (2011a) Photoresponsive DNA-cross-linked hydrogels for controllable release and cancer therapy. Langmuir 27:399-408
68. Kang H, Trondoli AC, Zhu G et al (2011b) Near-infrared light-responsive core-shell nanogels for targeted drug delivery. ACS Nano 5:5094-5099
69. Keefe AD, Cload ST (2008) SELEX with modified nucleotides. Curr Opin Chem Biol 12:448-456
70. Khati M, Schuman M, Ibrahim J et al (2003) Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers. J Virol 77:12692-12698 (Pubitemid 37430664)
71. Kim D, Jeong YY, Jon S (2010a) A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 4:3689-3696
72. Kim E, Jung Y, Choi H et al (2010b) Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 31:4592-4599
73. Kim JK, Choi KJ, Lee M et al (2012) Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 33:207-217
74. Kotula JW, Pratico ED, Ming X et al (2012) Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther 22:187-195
75. Kurosaki T, Higuchi N, Kawakami S et al (2012) Self-assemble gene delivery system for molecular targeting using nucleic acid aptamer. Gene 491:205-209
76. Kutok JL, Aster JC (2002) Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 20:3691-3702 (Pubitemid 34983230)
77. Lai YT, Destefano JJ (2012) DNA aptamers to human immunodeficiency virus reverse transcriptase selected by a primer-free SELEX method: characterization and comparison with other aptamers. Nucleic Acid Ther 22:162-176
78. Lee IH, An S, Yu MK et al (2011) Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J Control Release 155:435-441
79. Li N, Larson T, Nguyen HH et al (2010) Directed evolution of gold nanoparticle delivery to cells. Chem Commun 46:392-394
80. Li J, Feng L, Fan L et al (2011a) Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32:4943-4950
81. Li N, Nguyen HH, Byrom M et al (2011b) Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS ONE 6:e20299
82. Liu H, Moy P, Kim S et al (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629-3634 (Pubitemid 27381196)
83. Liu J, Liu H, Kang H et al (2012) Aptamer-incorporated hydrogels for visual detection, controlled drug release, and targeted cancer therapy. Anal Bioanal Chem 402:187-194
84. Long SB, Long MB, White RR et al (2008) Crystal structure of an RNA aptamer bound to thrombin. RNA 14:2504-2512
85. Lorenz C, Schroeder R (2006) Aptamers to antibiotics. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 116-130
86. Lupold SE, Hicke BJ, Lin Y et al (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62:4029-4033 (Pubitemid 34791070)
87. Mackie EJ (1997) Molecules in focus: tenascin-C. Int J Biochem Cell Biol 29:1133-1137 (Pubitemid 27522552)
88. Mallikaratchy P, Tang Z, Kwame S et al (2007) Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol Cell Proteomics 6:2230-2238
89. Mallikaratchy P, Tang Z, Tan W (2008) Cell specific aptamer- photosensitizer conjugates as a molecular tool in photodynamic therapy. Chem Med Chem 3:425-428
90. Mallikaratchy PR, Ruggiero A, Gardner JR et al (2011) A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res 39:2458-2469
91. McNamara JO 2nd, Andrechek ER, Wang Y et al (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24:1005-1015 (Pubitemid 44215395)
92. Melikyan GB, Markosyan RM, Hemmati H et al (2000) Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151:413-423
93. Meng L, Yang L, Zhao X et al (2012) Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. PLoS ONE 7:e33434
94. Mi J, Liu Y, Rabbani ZN et al (2010) In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol 6:22-24
95. Midwood KS, Hussenet T, Langlois B et al (2011) Advances in tenascin-C biology. Cell Mol Life Sci 68:3175-3199
96. Min K, Jo H, Song K et al (2011) Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials 32:2124-2132
97. Moore MD, Cookson J, Coventry VK et al (2011) Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics. J Biol Chem 286:2526-2535
98. Mori T, Oguro A, Ohtsu T et al (2004) RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. Nucleic Acids Res 32:6120-6128 (Pubitemid 40074006)
99. Mufhandu HT, Gray ES, Madiga MC et al (2012) UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. J Virol 86:4989-4999
100. Neff CP, Zhou J, Remling L et al (2011) An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 3:66ra66
101. Ng EW, Shima DT, Calias P et al (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123-132
102. Ni X, Castanares M, Mukherjee A et al (2011a) Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 18:4206-4214
103. Ni X, Zhang Y, Ribas J et al (2011b) Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 121:2383-2390
104. Nimjee SM, Rusconi CP, Sullenger BA (2005) Aptamers: an emerging class of therapeutics. Annu Rev Med 56:555-583 (Pubitemid 40299797)
105. Nimjee SM, Rusconi CP, Sullenger BA (2006) Aptamers to proteins. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 131-166
106. Oney S, Lam RT, Bompiani KM et al (2009) Development of universal antidotes to control aptamer activity. Nat Med 15:1224-1228
107. Ozalp VC, Eyidogan F, Oktem HA (2011) Aptamer-gated nanoparticles for smart drug delivery. Pharmaceuticals 4:1137-1157
108. Padilla R, Sousa R (1999) Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2′-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res 27:1561-1563 (Pubitemid 29206303)
109. Pinto JT, Suffoletto BP, Berzin TM et al (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445-1451 (Pubitemid 126447436)
110. Ramalingam D, Duclair S, Datta SA et al (2011) RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J Virol 85:305-314
111. Rapoport NY, Kennedy AM, Shea JE et al (2009) Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J Control Release 138:268-276
112. Ray P, Cheek MA, Sharaf ML et al (2012) Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Ther 22:295-305
113. Realini T, Ng EWM, Adamis AP (2006) Applications in the clinic: the anti-VEGF aptamer. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 443-460
114. Rusconi CP, Scardino E, Layzer J et al (2002) RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419:90-94 (Pubitemid 34987876)
115. Rusconi CP, Roberts JD, Pitoc GA et al (2004) Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22:1423-1428 (Pubitemid 39482862)
116. Ryou SM, Kim JM, Yeom JH et al (2011) Gold nanoparticle-assisted delivery of small, highly structured RNA into the nuclei of human cells. Biochem Biophys Res Commun 416:178-183
117. Samson M, Libert F, Doranz BJ et al (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725 (Pubitemid 26282179)
118. Shangguan D, Li Y, Tang Z et al (2006) Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 103:11838-11843 (Pubitemid 44215773)
119. Shangguan D, Cao ZC, Li Y et al (2007) Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin Chem 53:1153-1155 (Pubitemid 46867534)
120. Shangguan D, Cao Z, Meng L et al (2008a) Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res 7:2133-2139
121. Shangguan D, Meng L, Cao ZC et al (2008b) Identification of liver cancer-specific aptamers using whole live cells. Anal Chem 80:721-728 (Pubitemid 351206860)
122. Shieh YA, Yang SJ, Wei MF et al (2010) Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano 4:1433-1442
123. Shigdar S, Lin J, Yu Y et al (2011) RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 102:991-998
124. Singla AK, Garg A, Aggarwal D (2002) Paclitaxel and its formulations. Int J Pharm 235:179-192 (Pubitemid 34185449)
125. Soontornworajit B, Zhou J, Shaw MT et al (2010a) Hydrogel functionalization with DNA aptamers for sustained PDGF-BB release. Chem Commun (Camb) 46:1857-1859
126. Soontornworajit B, Zhou J, Zhang Z et al (2010b) Aptamer-functionalized in situ injectable hydrogel for controlled protein release. Biomacromolecules 11:2724-2730
127. Sooter LJ, Ellington AD (2002) Reflections on a novel therapeutic candidate. Chem Biol 9:857-858 (Pubitemid 35240904)
128. Soundararajan S, Chen W, Spicer EK et al (2008) The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res 68:2358-2365 (Pubitemid 351521810)
129. Srivastava M, Pollard HB (1999) Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 13:1911-1922 (Pubitemid 29517621)
130. Taghdisi SM, Abnous K, Mosaffa F et al (2010) Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer. J Drug Target 18:277-281
131. Tan L, Neoh KG, Kang ET et al (2011) PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. Macromol Biosci 11:1331-1335
132. Tan L, Gee Neoh K, Kang ET et al (2012) Designer tridentate mucin 1 aptamer for targeted drug delivery. J Pharm Sci 101:1672-1677
133. Tang Z, Shangguan D, Wang K et al (2007) Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem 79:4900-4907 (Pubitemid 47051443)
134. Tasch J, Gong M, Sadelain M et al (2001) A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol 21:249-261 (Pubitemid 32959364)
135. Thiel KW, Giangrande PH (2010) Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv 1:849-861
136. Thiel KW, Hernandez LI, Dassie JP et al (2012) Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 40:6319-6337
137. Thomas MD, Srivastava B, Allman D (2006) Regulation of peripheral B cell maturation. Cell Immunol 239:92-102 (Pubitemid 44037540)
138. Tong GJ, Hsiao SC, Carrico ZM et al (2009) Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J Am Chem Soc 131:11174-11178
139. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510
140. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212 (Pubitemid 20149352)
141. Vavalle JP, Rusconi CP, Zelenkofske S et al (2012) A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. J Thromb Haemost 10:1303-1311
142. Wan Y, Kim YT, Li N et al (2010) Surface-immobilized aptamers for cancer cell isolation and microscopic cytology. Cancer Res 70:9371-9380
143. Wan Y, Mahmood MA, Li N et al (2012) Nanotextured substrates with immobilized aptamers for cancer cell isolation and cytology. Cancer 118:1145-1154
144. Wang J, Pantopoulos K (2011) Regulation of cellular iron metabolism. Biochem J 434:365-381
145. Wang CH, Huang YF, Yeh CK (2011) Aptamer-conjugated nanobubbles for targeted ultrasound molecular imaging. Langmuir 27:6971-6976
146. Wang CH, Kang ST, Lee YH et al (2012) Aptamer-conjugated and drug-loaded acoustic droplets for ultrasound theranosis. Biomaterials 33:1939-1947
147. Wheeler LA, Trifonova R, Vrbanac V et al (2011) Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 121:2401-2412
148. White RR, Sullenger BA, Rusconi CP (2000) Developing aptamers into therapeutics. J Clin Invest 106:929-934
149. Wu Y, Sefah K, Liu H et al (2010) DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc Natl Acad Sci USA 107:5-10
150. Xiao Z, Shangguan D, Cao Z et al (2008) Cell-specific internalization study of an aptamer from whole cell selection. Chemistry 14:1769-1775
151. Yang X, Liu X, Liu Z et al (2012) Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv Mater 24:2890-2895
152. Ye M, Hu J, Peng M et al (2012) Generating aptamers by cell-SELEX for applications in molecular medicine. Int J Mol Sci 13:3341-3353
153. Yin J, He X, Wang K et al (2012) One-step engineering of silver nanoclusters-aptamer assemblies as luminescent labels to target tumor cells. Nanoscale 4:110-112
154. Yu D, Wang D, Zhu FG et al (2009) Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J Med Chem 52:5108-5114
155. Yu C, Hu Y, Duan J et al (2011a) Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS ONE 6:e24077
156. Yu MK, Kim D, Lee IH et al (2011b) Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 7:2241-2249
157. Zhang P, Zhao N, Zeng Z et al (2009) Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. Lab Invest 89:1423-1432
158. Zhang M, Fabiilli ML, Haworth KJ et al (2010) Initial investigation of acoustic droplet vaporization for occlusion in canine kidney. Ultrasound Med Biol 36:1691-1703
159. Zhang K, Sefah K, Tang L et al (2012) A novel aptamer developed for breast cancer cell internalization. Chem Med Chem 7:79-84
160. Zhao N, Bagaria HG, Wong MS et al (2011) A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. J Nanobiotechnol 9:2
161. Zhao Y, Duan S, Zeng X et al (2012) Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm 9:1705-1716
162. Zhou J, Rossi JJ (2011) Aptamer-targeted RNAi for HIV-1 therapy. Methods Mol Biol 721:355-371
163. Zhou J, Li H, Li S et al (2008) Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 16:1481-1489
164. Zhou J, Swiderski P, Li H et al (2009) Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37:3094-3109
165. Zhou J, Shu Y, Guo P et al (2011) Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods 54:284-294
166. Zhu G, Meng L, Ye M et al (2012) Self-assembled aptamer-based drug carriers for bispecific cytotoxicity to cancer cells. Chem Asian J 7:1630-1636
167. Zueva E, Rubio LI, Duconge F et al (2011) Metastasis-focused cell-based SELEX generates aptamers inhibiting cell migration and invasion. Int J Cancer 128:797-804